South Korea’s MFDS approved Curocell’s Rimqarto (anbalcabtagene autoleucel; anbal-cel) on April 29, marking the first homegrown CAR T-cell therapy approval for advanced diffuse large B-cell lymphoma. The approval positions Rimqarto as a domestically developed option entering a market where CAR T has become a major category of cellular immunotherapy. The decision also underscores how regulators in emerging geographies are moving toward local manufacturing and locally developed clinical portfolios. For companies with similar programs, MFDS approvals can influence how quickly follow-on investments and trial designs are scaled. Rimqarto’s approval may also shift payer and provider planning in South Korea as health systems adapt to CAR T logistics, including bridging strategies and toxicity management. Regulatory acceptance will likely catalyze interest in domestic cell therapy ecosystem building—covering manufacturing capacity, quality systems, and clinical center workflows.